Met gepaste trots en enthousiasme laat DUOS weten professor Nick James internationaal toonaangevend op uro-oncologisch gebied en chief investigator van de baanbrekende STAMPEDE studie, te hebben aangetrokken als spreker over de abiraterone-arm van STAMPEDE op het DUOS Jaarsymposium 2017. Nick James sprak in 2015 ook op het DUOS Jaarsymposium, toen over de docetaxel-arm van de STAMPEDE studie. Het DUOS Jaarsymposium zal als vanouds plaatsvinden in Boerderij Mereveld te Utrecht op vrijdag 8 december.
In de komende weken zal er meer bekend worden over het programma. De inschrijving zal in september starten. Alle ontwikkelingen worden gecommuniceerd via de website en de wekelijkse (vrijdag) Nieuwsbrief.
Over professor Nick James:
Professor Nick James is Founding Director of the Warwick Cancer Research Unit and Professor of Clinical Oncology at the Queen Elizabeth Hospital Birmingham.
He co-founded the leading patient website CancerHelp UK (www.cancerhelp.org.uk) . His clinical practice and research are focussed on prostate, bladder and kidney cancer. His uro-oncology research spans phase I gene therapy trials to major phase III studies. Key achievements in prostate cancer include leading the first UK trial of gene therapy in prostate cancer, being UK chief investigator on the TAX327 study leading to the licensing of docetaxel for prostate cancer and being chief investigator on the STAMPEDE trial (http://www.stampedetrial.org). STAMPEDE is now the largest interventional study in prostate cancer with over 5000 patients recruited to date and features a novel multi-arm, multi stage design.
In the bladder cancer field he has lead a series of trials of chemoradiotherapy culminating in the BC2001 trial, the largest randomised trial in the field, published in the New England Journal of Medicine. The trial demonstrated that low dose synchronous chemotherapy combined with radiotherapy reduced invasive bladder cancer relapse rates by 43%.